^
    17d
    Immune Profiling of Psoriasiform Toxicity to Immune Checkpoint Inhibitor Therapy (ASDP 2024)
    These data suggest that differential upregulation of cytokine signaling pathways may be responsible for immunotherapy-related psoriasiform reactions versus de novo psoriasis. Additional studies are required to elucidate the mechanism of these cutaneous irAEs further.
    Checkpoint inhibition • IO biomarker
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • FOXA1 (Forkhead Box A1) • IL17A (Interleukin 17A) • KRT19 (Keratin 19) • IL1B (Interleukin 1, beta)
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    8ms
    Crown-like structures are associated with changes in immune cell infiltrates and gene signatures in patients with primary invasive breast cancer (ESMO-BC 2024)
    RNA sequencing showed that genes involved in cell proliferation were upregulated, whereas genes involved in the regulation of anticancer immunity were downregulated in CLS patients. Conclusions CLS were associated with an inflammatory border and aggressive molecular and immunosuppressive phenotypes in the core of the tumour.
    Clinical • Gene Signature • IO biomarker • Immune cell
    |
    HER-2 (Human epidermal growth factor receptor 2) • CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • CD68 (CD68 Molecule) • FCGR2A (Fc fragment of IgG receptor IIa) • FOXP3 (Forkhead Box P3) • FCGR2B (Fc Fragment Of IgG Receptor IIb)
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    9ms
    Differences in Immune Gene Expression Signatures and Biological Pathways Between Intracholecystic Papillary-Tubular Neoplasm with Associated Invasive Gallbladder Adenocarcinoma and Conventional Gallbladder Adenocarcinoma (USCAP 2024)
    Our findings illustrate transcriptomic differences between GBC and ICPN_GBC. Noteworthy, ICPN_GBC displayed an enhanced anti-tumor immunity with predominant T helper 1 response, while GBC had a pro-tumor immune response with high regulatory T cells. The understanding of the immune biology and biological pathways of these tumors can potentially optimize precision oncology for gallbladder cancer patients.
    IO biomarker
    |
    CDH1 (Cadherin 1) • LGALS1 (Galectin 1) • EPCAM (Epithelial cell adhesion molecule) • CD99 (CD99 Molecule) • ITGA5 (Integrin Subunit Alpha 5) • NECTIN2 (Nectin Cell Adhesion Molecule 2) • OCLN (Occludin)
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    12ms
    A transcriptomic approach to explore the immune landscape of patient with pancreatic ductal adenocarcinoma with prognostic impact. (ASCO-GI 2024)
    In this study, a prognostic transcriptomic-based signature of 14 genes has been defined and validated for PDAC. This signature clearly identifies two prognostic groups that could constitute the basis for tailored immunotherapy with specific IC inhibitors. LAG-3 is a promising target for immunotherapy in PDAC patients.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CD4 (CD4 Molecule) • TBX21 (T-Box Transcription Factor 21) • BTLA (B And T Lymphocyte Associated) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • SIGLEC5 (Sialic Acid Binding Ig Like Lectin 5)
    |
    PD-1 overexpression • PD-1 expression • LAG3 overexpression
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    1year
    Genomic staging of multifocal lung squamous cell carcinomas is independent of the comprehensive morphologic assessment. (PubMed, J Thorac Oncol)
    Staging of multifocal LSCC based on morphologic assessment is unreliable. Comprehensive genomic analyses should be adopted for the staging of multifocal LSCC.
    Journal • IO biomarker
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    over1year
    GENE EXPRESSION PROFILING OF T(14;18)-NEGATIVE CD23+ FOLLICLE CENTER LYMPHOMA DEMONSTRATES ACTIVATION OF THE IL4/JAK/STAT6 PATHWAY AND A ROLE IN ITS PATHOGENESIS (ICML 2023)
    GEP identified two distinct groups within t(14;18)-neg FL, indicating different stages of differentiation of the neoplastic B cells. FLnegmut shows activation of STAT6 pathway through upregulation of CD23 and IL4R and by enrichment in GSEA and correlates with CD23 expression. Constitutive activation of STAT6 and consequent upregulation of CD23 prevent ongoing B cell differentiation in FLnegmut, precluding the cells from exiting the GC and adopting the state of activated B cell.
    IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • TNFRSF17 (TNF Receptor Superfamily Member 17) • JAK1 (Janus Kinase 1) • CD22 (CD22 Molecule) • PAX5 (Paired Box 5) • STAT3 (Signal Transducer And Activator Of Transcription 3) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • S100A8 (S100 Calcium Binding Protein A8) • IRF4 (Interferon regulatory factor 4) • PTPN1 (Protein Tyrosine Phosphatase Non-Receptor Type 1) • SOCS1 (Suppressor Of Cytokine Signaling 1) • TYK2 (Tyrosine Kinase 2) • FCGR3A (Fc Fragment Of IgG Receptor IIIa) • CD40 (CD40 Molecule) • FCGR1A (Fc Fragment Of IgG Receptor Ia) • HLA-DMB (Major Histocompatibility Complex, Class II, DM Beta) • IL4 (Interleukin 4) • FCER2 (Fc Fragment Of IgE Receptor II) • FCRLA (Fc Receptor Like A) • IL4R (Interleukin 4 Receptor) • SLAMF7 (SLAM Family Member 7) • SOCS3 (Suppressor Of Cytokine Signaling 3) • TNFRSF13B (TNF Receptor Superfamily Member 13B)
    |
    SOCS1 mutation
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    over1year
    Tumor Microenvironment and Its Clinicopathologic and Prognostic Association in Cutaneous and Noncutaneous Angiosarcomas. (PubMed, Am J Clin Pathol)
    Our HTG analyses confirmed a high degree of tumor and microenvironment heterogeneity. Cutaneous ASs, ASs without MYC amplification, and ASs located in the head and neck area seem to be the most immunogenic subtypes in our series.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression • PD-L1 overexpression • MYC amplification • CD8 expression • PD-L1 amplification
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    almost2years
    Gene Expression Profile as a Therapeutic Biomarker for Classic Hodgkin Lymphoma Treated with Immunotherapy-Based Regimens (USCAP 2023)
    Background : PD-1 blockade treatment with nivolumab is effective in relapsed/refractory Classic Hodgkin Lymphoma (CHL)... IL13 and IL15 modulation may be a logical objective for future therapeutic strategies since their role in proliferation of HL-derived cell-lines in addition to JAK-STAT and MAPK signaling activation. Likewise, SOCS3 for its suppressive role in JAK-STAT pathway. Other dysregulated genes in our series with potential therapeutic targets should be SMAD7, FADD, NFKB1, and MAPK11due to their involvement in variety of process including cell growth and differentiation, apoptosis as well as immune response .
    PD(L)-1 Biomarker • Gene Expression Profile • IO biomarker
    |
    MAP2K1 (Mitogen-activated protein kinase kinase 1) • CCND1 (Cyclin D1) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • IL2 (Interleukin 2) • IL7R (Interleukin 7 Receptor) • S100A8 (S100 Calcium Binding Protein A8) • FADD (Fas associated via death domain) • MAPK1 (Mitogen-activated protein kinase 1) • ROR2 (Receptor Tyrosine Kinase Like Orphan Receptor 2) • S100A9 (S100 Calcium Binding Protein A9) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • CCL2 (Chemokine (C-C motif) ligand 2) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • TNFRSF4 (TNF Receptor Superfamily Member 4) • IL1A (Interleukin 1, alpha) • IL32 (Interleukin 32) • MLANA (Melan-A) • BAG4 (BAG Cochaperone 4) • CCL22 (C-C Motif Chemokine Ligand 22) • CDC20 (Cell Division Cycle 20) • CTSL (Cathepsin L) • ERCC6 (Excision repair cross-complementation group 6) • IL13 (Interleukin 13) • IL15 (Interleukin 15) • IL22 (Interleukin 22) • SMAD7 (SMAD Family Member 7) • ST6GAL1 (ST6 Beta-Galactoside Alpha-2,6-Sialyltransferase 1) • CD80 (CD80 Molecule) • CDCA8 (Cell Division Cycle Associated 8) • CDK3 (Cyclin Dependent Kinase 3) • CENPA (Centromere protein A) • HNF1A (HNF1 Homeobox A) • IFNL3 (Interferon Lambda 3) • IRAK1 (Interleukin 1 Receptor Associated Kinase 1) • KIF4A (Kinesin Family Member 4A) • KLRB1 (Killer Cell Lectin Like Receptor B1) • LGALS9 (Galectin 9) • MAGEA1 (MAGE Family Member A1) • MAGEC2 (MAGE Family Member C2) • MAP2K4 (Mitogen-Activated Protein Kinase Kinase 4) • MAPK11 (Mitogen-Activated Protein Kinase 11) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA) • PATZ1 (POZ/BTB And AT Hook Containing Zinc Finger 1) • PDHA1 (Pyruvate Dehydrogenase E1 Subunit Alpha 1) • POU2AF1 (POU Class 2 Homeobox Associating Factor 1) • SDHA (Succinate Dehydrogenase Complex Flavoprotein Subunit A) • SOCS3 (Suppressor Of Cytokine Signaling 3) • TGFBR1 (Transforming Growth Factor Beta Receptor 1) • TGIF2 (TGFB Induced Factor Homeobox 2)
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    |
    Opdivo (nivolumab)
    almost2years
    Prognostic classification of endometrial cancer according to transcriptomic-based immunophenotype (ESMO-GC 2023)
    These findings could be useful in the clinical management of the disease, constituting an open window in the selection of EC patients for immunotherapy. Legal entity responsible for the study The authors.
    PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CDK4 (Cyclin-dependent kinase 4) • TGFB1 (Transforming Growth Factor Beta 1) • TRIP13 (Thyroid Hormone Receptor Interactor 13) • RFC4 (Replication Factor C Subunit 4)
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    2years
    LAG3+ tumor infiltrating lymphocytes predict outcome in treatment naïve triple negative breast carcinoma (SABCS 2022)
    1. LAG3 is a prognostic marker for TNBCs. 2.
    Tumor-infiltrating lymphocyte • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • LAG3 (Lymphocyte Activating 3)
    |
    LAG3 expression
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    over2years
    Distinct immune gene programs associated with host tumor immunity, neoadjuvant chemotherapy and chemoimmunotherapy in resectable NSCLC. (PubMed, Clin Cancer Res)
    Our findings highlight immune gene programs that may underlie host tumor immunity and response to neoadjuvant chemotherapy and chemoimmunotherapy in resectable NSCLC.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8)
    |
    PD-L1 expression
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    over2years
    Distinct immune gene programs associated with host tumor immunity, neoadjuvant chemotherapy and chemoimmunotherapy in resectable NSCLC (AACR 2022)
    Our findings highlight immune gene programs that may underlie host tumor immunity and response to neoadjuvant chemotherapy and chemoimmunotherapy in early-stage NSCLC.
    Clinical • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8)
    |
    PD-L1 expression
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    over2years
    The combination of hyper-amplification and tumor mutational burden as a pan-cancer biomarker in patients treated with tislelizumab (AACR 2022)
    The combination of TMB and HA was found to be predictive of clinical benefit across various solid tumor types, treated with tislelizumab. This joint algorithm, as reported by one clinically approved assay, may provide new insights to the identification of pts who are most likely to gain benefit from PD-(L)1 blockade.
    Late-breaking abstract • Clinical • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Pan tumor
    |
    TMB (Tumor Mutational Burden)
    |
    TMB-H
    |
    FoundationOne® CDx • HTG EdgeSeq Precision Immuno-Oncology Panel
    |
    Tevimbra (tislelizumab-jsgr)
    over2years
    CD8 T cells and macrophage abundances associated with clinical benefit of tislelizumab in various tumor types (AACR 2022)
    Co-enrichment of CD8 T cells and macrophages were associated with survival benefit and an immune-activated TME in pts with various tumor types treated with TIS. This observation warrants further investigation.
    Late-breaking abstract • Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CD68 (CD68 Molecule) • GZMB (Granzyme B) • GZMA (Granzyme A) • STAT1 (Signal Transducer And Activator Of Transcription 1) • TAP1 (Transporter 1) • SLAMF7 (SLAM Family Member 7)
    |
    KIT expression • CD8-H
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    |
    Tevimbra (tislelizumab-jsgr)
    almost3years
    MAGE Family of Cancer Testis Antigen Genes are Associated with Resistance to Immune Checkpoint Inhibitors in Sarcomatoid Renal Cell Carcinomas (USCAP 2022)
    Design: The study cohort consisted of patients with surgically resected sarcomatoid RCC of clear cell subtype(sccRCC), with no neoadjuvant therapy and who subsequently received an ICI therapy regimen (ipilimumab/nivolumab) after resection. Our data suggest that some cancer-testis antigen genes, particularly MAGE family genes, may serve as biomarkers of resistance to ICI based therapy in sccRCC. These findings warrant validation using orthogonal assays and in broader RCC patient cohorts.
    Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    almost3years
    Increased Expression of Immune Checkpoint Regulators LAG3 and CD70 in the Tumor Cells and Microenvironment in Immunodeficiency Associated Lymphoproliferative Disorders (USCAP 2022)
    LAG3 and CD70 are expressed in IA-LD. Although CD70 is highly expressed in TC and TME, LAG3 is mainly expressed in TME. EBV infection is associated with high expression of CD70 and LAG3 in TME.
    PD(L)-1 Biomarker • IO biomarker
    |
    LAG3 (Lymphocyte Activating 3) • CD70 (CD70 Molecule)
    |
    CD70 expression • LAG3 expression
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    almost3years
    Single Region Sampling Does Not Capture the Intra-Tumoral Immune Heterogeneity of Sarcomatoid Renal Cell Carcinoma (USCAP 2022)
    Our data suggest that single region sampling may not capture the intra-tumoral immune heterogeneity of sRCC. Further, it appears that the S- component is more immunosuppressive despite similar proportions of immune cell types between E- and S- components of sRCC.
    PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CD276 (CD276 Molecule) • CD44 (CD44 Molecule) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    almost3years
    MAGE Family of Cancer Testis Antigen Genes are Associated with Resistance to Immune Checkpoint Inhibitors in Sarcomatoid Renal Cell Carcinomas (USCAP 2022)
    Design: The study cohort consisted of patients with surgically resected sarcomatoid RCC of clear cell subtype(sccRCC), with no neoadjuvant therapy and who subsequently received an ICI therapy regimen (ipilimumab/nivolumab) after resection. Our data suggest that some cancer-testis antigen genes, particularly MAGE family genes, may serve as biomarkers of resistance to ICI based therapy in sccRCC. These findings warrant validation using orthogonal assays and in broader RCC patient cohorts.
    Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    3years
    Bone Marrow Lymphoid Infiltrates and Aplasia after CD19-Directed CAR T Cell Therapy in Pediatric B-Lymphoblastic Leukemia (ASH 2021)
    C and D. Sustained responders show significantly greater CD3+ T cells after CAR T cell infusion compared to other categories. *P<0.05.
    CAR T-Cell Therapy • Clinical • IO biomarker
    |
    CD19 (CD19 Molecule) • CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • GZMA (Granzyme A)
    |
    CD19 positive
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    3years
    Bone Marrow Biopsy T Cell Aggregates and Cytokine Transcriptional Signatures Predict Sustained Response to CAR T-Cell Therapy in B-ALL (ASH 2021)
    SR to CAR19 is also associated with elevated marrow expression of a suite of immune chemoattractants which may enhance the ability of infused CAR T cells and other effectors to infiltrate the B-ALL microenvironment. Combined assessment of bone marrow T cell infiltrates and transcriptional profiling could be used to improve the sensitivity and specificity of predictive algorithms for responses to CAR19 therapy.
    CAR T-Cell Therapy • IO biomarker
    |
    CD19 (CD19 Molecule) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • IL17A (Interleukin 17A) • CXCL5 (Chemokine (C-X-C motif) ligand 5) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • IL13 (Interleukin 13)
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    3years
    Distinct immune gene programs associated with host tumor immunity, neoadjuvant chemotherapy and chemoimmunotherapy in resectable NSCLC (ESMO-IO 2021)
    Legal entity responsible for the study The University of Texas MD Anderson Cancer Center. Funding MD Anderson Cancer Center.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
    |
    PD-L1 expression
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    3years
    Tumor-immune signatures associated with response or resistance to tislelizumab in patients with previously treated advanced hepatocellular carcinoma (HCC) (SITC 2021)
    Further GEP analyses will be undertaken in an on-going Phase 3 study (NCT03412773). Trial Registration NCT03419897
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • CD4 (CD4 Molecule) • CXCL13 (Chemokine (C-X-C motif) ligand 13)
    |
    CD8 expression
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    |
    Tevimbra (tislelizumab-jsgr)
    3years
    Targeted gene expression profiling of inverted papilloma and squamous cell carcinoma. (PubMed, Int Forum Allergy Rhinol)
    "Progressive upregulation of genes specific to IP malignant degeneration has significant clinical implications. This panel of 11 genes will improve concordance of histologic classification, which can directly impact treatment and patient outcomes. Additionally, future studies on larger tumor sets may observe upregulation in the gene panel that preceded histologic changes, which may be useful for further risk stratification."
    Journal
    |
    LGALS1 (Galectin 1) • COL1A1 (Collagen Type I Alpha 1 Chain) • COL3A1 (Collagen Type III Alpha 1 Chain) • MMP11 (Matrix Metallopeptidase 11) • COL5A2 (Collagen Type V Alpha 2 Chain) • ITGA5 (Integrin Subunit Alpha 5)
    |
    HTG EdgeSeq Oncology Biomarker Panel (OBP) • HTG EdgeSeq Precision Immuno-Oncology Panel
    over3years
    [VIRTUAL] TA-ness classification discriminates RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) who may benefit from antiEGFR treatment (ESMO 2021)
    We aimed to evaluate different gene-expression–based classifiers for identification of RAS wt pts that may benefit from antiEGFR. RNA was extracted from FFPE slides obtained from 74 RAS wt mCRC pts treated with cetuximab (Cmab) or panitumumab (Pmab) from a retrospective multicentre study. TA-high subtype was associated with better OS in RAS wt mCRC pts treated with Cmab/Pmab suggesting TA-ness classification may be useful for antiEGFR treatment selection. Further analyses from prospective clinical trials are necessary to validate our .
    Clinical • IO biomarker
    |
    BRAF (B-raf proto-oncogene)
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    |
    Erbitux (cetuximab) • Vectibix (panitumumab)
    over3years
    [VIRTUAL] Identifying Immuno-Oncology Markers for Drug-Resistant Neuroblastoma via a Murine Xenograft Model. (EACR 2021)
    "Material and Methods Cisplatin-sensitive KellyLuc cells, and resistant KellyCis83Luc cells, were injected via the tail vein of mice, establishing metastatic disease...SOCS3 is a key negative feedback regulator of JAK/STAT signalling, and low expression correlates with increased immunosuppression and poor outcomes in other cancers, demonstrating its potential as an immuno-oncology marker in NB. TNFRSF4 is necessary in the activation of T-cells, and its receptor is often expressed on activated macrophages, making it a key player worth further investigation in the interactions which lead to an effective immune response."
    Preclinical
    |
    TNFRSF4 (TNF Receptor Superfamily Member 4)
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    |
    cisplatin
    over3years
    [VIRTUAL] Molecular High Grade (MHG) gene expression profile in DLBCL is enriched among patients with early treatment failure (ICML 2021)
    MHG was more frequently identified in the early progressor cohort, suggesting that MHG GEP contributes to poor response to conventional R-CHOP treatment for DLBCL. Prospective identification of this group for testing more effective treatment strategies is a priority.
    Clinical • Gene Expression Profile
    |
    HTG EdgeSeq Pan B-Cell Lymphoma Panel • HTG EdgeSeq Precision Immuno-Oncology Panel
    |
    Rituxan (rituximab)
    over3years
    [VIRTUAL] Diagnostic ability of four cell-free miRNA signatures pre- and post-nephrectomy concordantly found in the tumor and blood from patients with renal cell carcinoma. (ASCO 2021)
    Our results propose a four cfmiR signature as a potential diagnostic/monitoring urine biomarker that is also detectable in the plasma and tumor tissues from RRC . Further studies to validate these cfmiRNAs as biomarkers for RCC in blood and urine are ongoing.
    Clinical
    |
    MIR23b (MicroRNA 23b) • MIR30D (MicroRNA 30d)
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel • HTG EdgeSeq miRNA Whole Transcriptome Assay
    over3years
    [VIRTUAL] Gene expression profiling signatures for immunophenotyping of tumor microenvironment using HTG EdgeSeq Precision Immuno-Oncology Panel. (ASCO 2021)
    These immunophenotyping signatures provide a suite of robust tools for the characterization of the tumor microenvironment in order to better understand the tumor immune biology and mechanisms of resistance to immunotherapy . The signature scores can typically be generated from a single section of FFPE tissue using HTG’s extraction-free GEP technology and a fully automated bioinformatic pipeline available in the HTG EdgeSeq Reveal software.
    IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel
    over3years
    [VIRTUAL] Subgroup of post-neoadjuvant luminal-B tumors assessed by HTG in PENELOPE-B investigating palbociclib in high risk HER2-/HR+ breast cancer with residual disease. (ASCO 2021)
    PENELOPE-B did not show a benefit from the addition of 1 year palbociclib to endocrine therapy compared to placebo in the total enrolled high-risk primary breast cancer population . However, the small group of luminal-B tumors (n = 64) derived benefit from palbociclib, although without a statistically significant interaction . Further investigation is required in a larger cohort to validate a palbociclib benefit that might be confined to this group.
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2) • CDK4 (Cyclin-dependent kinase 4)
    |
    HR positive • HER-2 negative
    |
    HTG EdgeSeq Oncology Biomarker Panel (OBP) • HTG EdgeSeq Precision Immuno-Oncology Panel
    |
    Ibrance (palbociclib)
    over3years
    [VIRTUAL] MamaPred: A new and innovative approach to determine recurrence risk in HR+/HER2- early-stage breast cancer using HTG EdgeSeq technology. (ASCO 2021)
    MamaPred identifies HR+/HER2- early-stage BC patients with high-risk of distant relapse improving the prognostic value of those studies that compare MP and OT, suggesting a more precise risk classification.
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • EGFR positive
    |
    HTG EdgeSeq Oncology Biomarker Panel (OBP) • MammaPrint • HTG EdgeSeq Precision Immuno-Oncology Panel
    over3years
    [VIRTUAL] CCNE1 mRNA and cyclin E1 protein expression as predictive biomarkers for efficacy of palbociclib plus fulvestrant versus capecitabine in the phase III PEARL study. (ASCO 2021)
    High tumor CCNE1 mRNA expression identified patients with relative resistance to palbociclib plus fulvestrant, validating prior observations although without statistical significance for interaction . Assessment of Cyclin E1 protein expression did not show predictive value . Investigation treatments to enhance CDK4/6 inhibitor efficacy in tumors with high CCNE1 expression is warranted.
    P3 data • Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2) • CCNE1 (Cyclin E1)
    |
    HR positive • HER-2 negative • CCNE1 overexpression • CCNE1 expression • CCNE1 elevation
    |
    HTG EdgeSeq Oncology Biomarker Panel (OBP) • HTG EdgeSeq Precision Immuno-Oncology Panel
    |
    Ibrance (palbociclib) • capecitabine • fulvestrant
    almost4years
    [VIRTUAL] Impact of Immunodeficiency on the Tumor Microenvironment in EBV-Positive Diffuse Large B-cell Lymphoma. Exploratory Study Using Gene Expression Analysis (USCAP 2021)
    Our results indicate that the nature of the underlying immunodeficiency impacts the TME in EBV+ DLBCL. However, the distinctive EBV+ immunodeficiency associated LPD share common deregulated immune pathways related to the presence of EBV and its latent proteins. Additionally, we identified potential biomarkers, which may help implement personalized therapies.
    PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • IL6 (Interleukin 6) • LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • PD-L2 (Programmed Cell Death 1 Ligand 2) • CD163 (CD163 Molecule) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD70 (CD70 Molecule) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • FASLG (Fas ligand) • ICOS (Inducible T Cell Costimulator) • TGFB1 (Transforming Growth Factor Beta 1) • FOXP3 (Forkhead Box P3) • IL17A (Interleukin 17A) • MMP9 (Matrix metallopeptidase 9)
    |
    CD70 expression • FOXP3 expression
    |
    HTG EdgeSeq Precision Immuno-Oncology Panel